

Prof. YILMAZ ÇAPAN

Personal Information

Email: ycapan@hacettepe.edu.tr

International Researcher IDs

ORCID: 0000-0003-1234-9018

ScopusID: 6603768177

Yoksis Researcher ID: 105883

Education Information

Doctorate, Universite de Lille II, Pharmaceutical Technology, France 1976 - 1978

Postgraduate, Universite de Lille II, Industrial Pharmaceutical Technology, France 1974 - 1976

Undergraduate, Hacettepe University, Eczacılık Fakültesi, Turkey 1968 - 1972

Foreign Languages

French, C1 Advanced

English, C1 Advanced

Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutics Technology, Pharmaceutical Technology

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier**
Seko I., TONBUL H., Tavukcuoglu E., Sahin A., AKBAŞ S., Yanik H., ÖZTÜRK S. C., ESENDAĞLI G., Khan M., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.66, 2021 (SCI-Expanded)
- II. **Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells**
TONBUL H., Sahin A., Tavukcuoglu E., Ultav G., AKBAŞ S., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.63, 2021 (SCI-Expanded)
- III. **Fractionated charge variants of biosimilars: A review of separation methods, structural and functional analysis**
YÜCE M., Sert F., Torabfam M., Parlar A., Gurel B., Cakir N., Daglikoca D. E., Khan M. A., capan Y.
ANALYTICA CHIMICA ACTA, vol.1152, 2021 (SCI-Expanded)
- IV. **Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer**
Tonbul H., Sahin A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.54, 2019 (SCI-Expanded)
- V. **Nanopharmaceuticals as Drug-Delivery Systems: For, Against, and Current Applications**
ÇALIŞ S., ÖZTÜRK ATAR K., ARSLAN F. N., EROĞLU H., ÇAPAN Y.

NANOCARRIERS FOR DRUG DELIVERY: NANOSCIENCE AND NANOTECHNOLOGY IN DRUG DELIVERY, pp.133-154, 2019 (SCI-Expanded)

- VI. **DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING HPLC METHOD FOR DIFLUCORTOLONE VALERATE AND ISOCONAZOLE NITRATE COMBINATION**
Gundogdu S. O., Simsek F., Doganay A., Capan Y.
ACTA POLONIAE PHARMACEUTICA, vol.76, no.1, pp.49-58, 2019 (SCI-Expanded)
- VII. **Nano-Based Carriers for Brain Drug Delivery**
ÖZTÜRK ATAR K., Ozkan M., EROĞLU H., ÇAPAN Y.
CHARACTERIZATION AND BIOLOGY OF NANOMATERIALS FOR DRUG DELIVERY: NANOSCIENCE AND NANOTECHNOLOGY IN DRUG DELIVERY, pp.563-586, 2019 (SCI-Expanded)
- VIII. **Synthesis of Small-Sized Mesoporous Silica Nanoparticles by Experimental Design and Characterization for Further Drug Delivery**
TONBUL H., Ultav G., AKBAŞ S., Sahin A., AKTAŞ Y., ÇAPAN Y.
LATIN AMERICAN JOURNAL OF PHARMACY, vol.38, no.11, pp.2204-2210, 2019 (SCI-Expanded)
- IX. **Characterization of bevacizumab by dynamic light scattering while maintaining its native structure**
Akbas S., Sahin A., ÇALIŞ S., Oncel H., ÇAPAN Y.
PHARMAZIE, vol.73, no.7, pp.369-374, 2018 (SCI-Expanded)
- X. **Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles**
Kozlu S., Sahin A., Ultav G., Yerlikaya F., ÇALIŞ S., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.45, pp.213-219, 2018 (SCI-Expanded)
- XI. **Preparation and Characterization of Biocompatible Chitosan Nanoparticles for Targeted Brain Delivery of Peptides**
Yemisci M., Caban S., Fernandez-Megia E., ÇAPAN Y., Couvreur P., DALKARA T.
NEUROTROPIC FACTORS: METHODS AND PROTOCOLS, 2ND EDITION, vol.1727, pp.443-454, 2018 (SCI-Expanded)
- XII. **Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)**
Kozlu S., ŞAHİN A. E., ÇALIŞ S., ÇAPAN Y.
PHARMAZIE, vol.72, no.10, pp.568-570, 2017 (SCI-Expanded)
- XIII. **DEVELOPMENT AND VALIDATION OF HPLC ANALYTICAL METHODS USED FOR DETERMINATION OF ASSAY, CONTENT UNIFORMITY AND DISSOLUTION OF IMMEDIATE RELEASE CANDESARTAN CILEXETIL 32 MG TABLETS**
YÜCE M., ÇAPAN Y.
ACTA POLONIAE PHARMACEUTICA, vol.74, no.2, pp.357-367, 2017 (SCI-Expanded)
- XIV. **A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery**
ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., Caban-Toktas S., Yoyen-Ermis D., HORZUM U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, vol.45, no.8, pp.1657-1664, 2017 (SCI-Expanded)
- XV. **Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells**
Sahin A., Yoyen-Ermis D., Caban-Toktas S., Horzum U., AKTAŞ Y., Couvreur P., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF MICROENCAPSULATION, vol.34, no.7, pp.659-666, 2017 (SCI-Expanded)
- XVI. **Preformulation of Immediate Release Candesartan Cilexetil Tablets Using Full Factorial Experimental Design**
YÜCE M., GÜVEN O., KARAHAN S., SARAÇBAŞI O., ÇAPAN Y.
LATIN AMERICAN JOURNAL OF PHARMACY, vol.35, no.5, pp.921-930, 2016 (SCI-Expanded)
- XVII. **Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection**
Yemisci M., Caban S., Gursoy-Ozdemir Y., Lule S., NOVOA-CARBALLAL R., RIGUERA R., FERNANDEZ-MEGIA E.,

- Andrieux K, COUVREUR P, ÇAPAN Y, et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol.35, no.3, pp.469-475, 2015 (SCI-Expanded)
- XVIII. **Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury**
Gaudin A, Yemisci M, EROĞLU H, Lepetre-Mouelhi S, Turkoglu O. F., Donmez-Demir B., Caban S., SARGON M. F., Garcia-Argote S, Pieters G, et al.
NATURE NANOTECHNOLOGY, vol.9, no.12, pp.1054-1062, 2014 (SCI-Expanded)
- XIX. **An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design**
KOZLU S, CABAN S, YERLIKAYA F, FERNANDEZ-MEGIA E, NOVOA-CARBALLAL R, RIGUERA R, Yemisci M, GURSOY-OZDEMIR Y, DALKARA T, COUVREUR P, et al.
PHARMAZIE, vol.69, no.5, pp.340-345, 2014 (SCI-Expanded)
- XX. **Comparative in vitro studies on PBN loaded nanoparticles prepared by biodegradable chitosan, PLGA polymers and their PEGylated block copolymers**
Ozturk K, FERNANDEZ-MEGIA E, NOVOA-CARBALLAL R, RIGUERA R, Yemisci M, GURSOY-OZDEMIR Y, DALKARA T, COUVREUR P, ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.24, no.2, pp.148-152, 2014 (SCI-Expanded)
- XXI. **Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design Approach**
Yerlikaya F, Ozgen A, VURAL İ, Guven O, Karaagaoglu E, Khan M. A., ÇAPAN Y.
JOURNAL OF PHARMACEUTICAL SCIENCES, vol.102, no.10, pp.3748-3761, 2013 (SCI-Expanded)
- XXII. **Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression**
OLMEZ S. S., VURAL İ, ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
PHARMAZIE, vol.68, no.2, pp.110-116, 2013 (SCI-Expanded)
- XXIII. **CHARACTERIZATION, CELL PROLIFERATION AND CYTOTOXICITY EVALUATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LOADED POLY (LACTIC-CO-GLYCOLIC ACID) MICROSPHERES**
KERİMOĞLU O., ALARÇIN E., Turkoglu M., Dortunc B., Karagoz H., Ulkur E., VURAL İ., ÇAPAN Y.
NOBEL MEDICUS, vol.8, no.1, pp.77-82, 2012 (SCI-Expanded)
- XXIV. **TRANSPORT OF A CASPASE INHIBITOR ACROSS THE BLOOD BRAIN BARRIER BY CHITOSAN NANOPARTICLES**
YEMISCI M., GURSOY-OZDEMIR Y., CABAN S., BODUR E., ÇAPAN Y., DALKARA T.
NANOMEDICINE: CANCER, DIABETES, AND CARDIOVASCULAR, CENTRAL NERVOUS SYSTEM, PULMONARY AND INFLAMMATORY DISEASES, vol.508, pp.253-269, 2012 (SCI-Expanded)
- XXV. **Evaluation of drug-exciipient interaction in the formulation of celecoxib tablets**
Bozdog-Pehlivan S., Subasi B., VURAL İ., Unlu N., ÇAPAN Y.
Acta Poloniae Pharmaceutica - Drug Research, vol.68, no.3, pp.423-433, 2011 (SCI-Expanded)
- XXVI. **Comparative evaluation of in vitro parameters of tamoxifen citrate loaded poly(lactide-co-glycolide), poly(ϵ -caprolactone) and chitosan nanoparticles**
Cirpanli Y., Yerlikaya F., Ozturk K., Erdogar N., Launay M., Gegu C., Leturgez T., BİLENSOY E., ÇALIŞ S., ÇAPAN Y.
Pharmazie, vol.65, no.12, pp.867-870, 2010 (SCI-Expanded)
- XXVII. **LC-UV Determination of Melatonin from Chitosan Nanoparticles**
Yerlikaya F., Aktas Y., ÇAPAN Y.
CHROMATOGRAPHIA, vol.71, pp.967-970, 2010 (SCI-Expanded)
- XXVIII. **A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection**
KARATAS H., AKTAS Y., GURSOY-OZDEMIR Y., BODUR E., YEMISCI M., CABAN S., VURAL A., PINARBASLI O., ÇAPAN Y., FERNANDEZ-MEGIA E., et al.
Journal of Neuroscience, vol.29, no.44, pp.13761-13769, 2009 (SCI-Expanded)
- XXIX. **ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TAMOXIFEN CITRATE USING NORMAL PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY**
Yerlikaya F., Launay M., Gegu C., Leturgez T., BİLENSOY E., ÇALIŞ S., ÇAPAN Y.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.183-184, 2009 (SCI-Expanded)
- XXX. **Microbiological and clinical comparison of chlorhexidine buccoadhesive tablet and chlorhexidine**

mouthrinse

AKTAŞ A., GIRAY B., ÇAPAN Y., MENEMENLIOĞLU D., HAYRAN M., İKİNCİ G., VURAL İ.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.19, no.5, pp.353-357, 2009 (SCI-Expanded)

- XXXI. **Preparation and Characterization of Salmon Calcitonin-biotin Conjugates**
ÇETİN M., Youn Y. S., ÇAPAN Y., Lee K. C.
AAPS PHARMSCITECH, vol.9, no.4, pp.1191-1197, 2008 (SCI-Expanded)
- XXXII. **Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity**
Na D. H., Faraj J., Capan Y., Leung K. P., DeLuca P. P.
PHARMACEUTICAL RESEARCH, vol.24, no.8, pp.1544-1550, 2007 (SCI-Expanded)
- XXXIII. **Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system**
Faraj J. A., Dorati R., Schoubben A., Worthen D., Selmin F., Capan Y., Leung K., DeLuca P. P.
AAPS PHARMSCITECH, vol.8, no.1, 2007 (SCI-Expanded)
- XXXIV. **Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain**
KİLİC A. C., Capan Y., Vural I., Gursoy R. N., Dalkara T., CUİNE A., HİNCAL A. A.
JOURNAL OF MICROENCAPSULATION, vol.22, no.6, pp.633-641, 2005 (SCI-Expanded)
- XXXV. **Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor**
AKTAŞ Y., ANDRİEUX K., ALONSO M. J., CALVO P., Gursoy R. N., COUVREUR P., Capan Y.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.298, no.2, pp.378-383, 2005 (SCI-Expanded)
- XXXVI. **Mitoxantrone loaded poly(DL-lactide-co-glycolide) microspheres for treatment of brain tumors I. formulation and release characteristics**
Bozdağ S., ÇAPAN Y., VURAL İ., Hincal A., DeLuca P.
Technology and Health Care, vol.10, pp.353-355, 2002 (SCI-Expanded)
- XXXVII. **In vitro/in vivo studies on a buccal bioadhesive tablet formulation of carbamazepine**
İKİNCİ G., ÇAPAN Y., ŞENEL S., Alaaddinoglu E., DALKARA T., Hincal A.
Pharmazie, vol.55, no.10, pp.762-765, 2000 (SCI-Expanded)
- XXXVIII. **Formulation and in vitro in vivo investigation of carbamazepine controlled-release matrix tablets**
İkinci G., Capan Y., Senel S., Dalkara T., Hincal A.
PHARMAZIE, vol.54, no.2, pp.139-141, 1999 (SCI-Expanded)
- XXXIX. **Histological and bioadhesion studies on buccal bioadhesive tablets containing a penetration enhancer sodium glycodeoxycholate**
Senel S., Capan Y., Sargon M. F., Giray C. B., Hincal A.
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.170, no.2, pp.239-245, 1998 (SCI-Expanded)
- XL. **In vitro studies on enhancing effect of sodium glycocholate on transbuccal permeation of morphine hydrochloride**
Senel S., Duchene D., Hincal A., Capan Y., Ponchel G.
JOURNAL OF CONTROLLED RELEASE, vol.51, pp.107-113, 1998 (SCI-Expanded)
- XLI. **Enhancement of transbuccal permeation of morphine sulfate by sodium glycodeoxycholate in vitro**
Senel S., Capan Y., Sargon M. F., İkinci G., Solpan D., Guven O., Bodde H., Hincal A.
JOURNAL OF CONTROLLED RELEASE, vol.45, no.2, pp.153-162, 1997 (SCI-Expanded)

Articles Published in Other Journals

- I. **Silica nanoparticle synthesis by experimental design for drug and gene delivery applications**
Ultav G., TONBUL H., ŞAHİN A., ÇAPAN Y.
Journal of Research in Pharmacy, vol.27, no.1, pp.12-22, 2023 (Scopus)
- II. **Brain-targeted nanoparticles to overcome the blood-brain barrier**
SEKO I., ŞAHİN A., TONBUL H., ÇAPAN Y.
Journal of Pharmaceutical Technology, vol.1, no.1, pp.26-40, 2020 (Peer-Reviewed Journal)

- III. **Development of paclitaxel and flurbiprofen co-loaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett-Burman design**
Sahin A., Caban-Toktas S., Tonbul H., Yerlikaya F., AKTAŞ Y., ÇAPAN Y.
ISTANBUL JOURNAL OF PHARMACY, vol.49, no.3, pp.161-166, 2019 (ESCI)
- IV. **Beyine İlaç Taşınması:Truva Atı Teknolojisi**
DOĞAN S. S., TOKTAŞ S., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, 2014 (Peer-Reviewed Journal)
- V. **Formulation and in vitro evaluation of paclitaxel loaded nanoparticles Paklitaksel yüklü nanopartiküllerin formülasyonu ve in vitro incelenmesi**
Aygül G., Yerlikaya F., Caban S., VURAL İ., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.33, no.1, pp.25-40, 2013 (Scopus)
- VI. **Beyine İlaç Hedeflendirme Stratejileri**
DOĞAN S. S., TOKTAŞ S., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, 2013 (Peer-Reviewed Journal)
- VII. **Preparation and characterization of biocompatible chitosan nanoparticles for targeted brain delivery of peptides.**
Caban S., Capan Y., Couvreur P., Dalkara T.
Methods in molecular biology (Clifton, N.J.), vol.846, pp.321-32, 2012 (Scopus)
- VIII. **Orally disintegrating tablets ii: In vitro and in vivo evaluations Ağızda dağılan tabletler ii: In vitro ve in vivo değerlendirilmeleri**
Ölmez S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.31, no.1, pp.59-70, 2011 (Scopus)
- IX. **Orally disintegrating tablets i: Preparation technologies Ağızda dağılan tabletler i: Hazırlama teknolojileri**
Ölmez S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.
Hacettepe University Journal of the Faculty of Pharmacy, vol.30, no.2, pp.205-230, 2010 (Scopus)
- X. **Etodolac loaded poly (lactide-co-glycolide) nanoparticles: Formulation and in vitro characterization Etodolak yüklü poli (Laktid-ko-glikolid) nanopartikülleri: Formülasyon ve in vitro karakter**
Çirpanli Y., Robineau C., ÇAPAN Y., ÇALIŞ S.
Hacettepe University Journal of the Faculty of Pharmacy, vol.29, no.2, pp.105-114, 2009 (Scopus)
- XI. **Desensitization to allopurinol in a patient with fixed drug eruption**
Damadoglu E., Isik S. R., KARAKAYA G., ÇAPAN Y., KALYONCU A. F.
ASTIM ALLERJİ IMMUNOLOJİ, vol.7, no.3, pp.194-197, 2009 (ESCI)
- XII. **Preparation and characterization of BSA-loaded alginate microspheres**
ÇETİN M., VURAL İ., ÇAPAN Y., Hincal A. A.
Fabad Journal of Pharmaceutical Sciences, vol.32, no.3, pp.103-107, 2007 (Scopus)
- XIII. **Method Validation in Determination of Mitoxantrone by HPLC**
Bozdağ S., ÇAPAN Y., VURAL İ., Hincal A. A.
Acta Pharmaceutica Turcica, vol.46, no.1, pp.43-47, 2004 (Scopus)
- XIV. **Formulation and in Vitro-in Vivo Evaluation of Buccoadhesive Morphine Sulfate Tablets**
Anlar Ş., ÇAPAN Y., Güven O., GÖĞÜŞ A., DALKARA T., Hincal A.
Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists, vol.11, no.2, pp.231-236, 1994 (Scopus)
- XV. **Formulation, Bioavailability, and Pharmacokinetics of Sustained-Release Potassium Chloride Tablets**
ŞENEL S., ÇAPAN Y., DALKARA T., İnanç N., Hincal A. A.
Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists, vol.8, no.10, pp.1313-1317, 1991 (Scopus)

- I. **Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of Doxorubicin In Breast Cancer**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKCUOĞLU E., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019, vol.1, pp.184-186
- II. **PREPERATION, CHARACTERIZATION, CYTOTOXICITY EVALUATIONS OFFOLIC ACID CONJUGATED MESOPOROUS SILICA NANOPARTICLES**
TONBUL H., ultav g., akbas s., sahin a., tavukcuoglu e., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
19th InternationalPharmaceutical Technology Symposium-IPTS 2018, 17 - 19 September 2018
- III. **DEVELOPMET AND EVALUATION OF SILICA NANOPARTICLES USING A QUALITY BY DESIGN APPROACH**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.
EUFEPS Annual Meeting 2018, 24 - 26 May 2018
- IV. **IN VITRO EVALUATION OF PACLITAXEL LOADED MESOPOROUS SILICA NANOPARTICLES**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.
EUFEPS Annual Meeting 2018, 24 - 26 May 2018
- V. **Synthesis and Characterization of Silica Nanoparticles: Obtaining nanoparticles smaller than 100 nm**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., KAYNAK M. S., AKTAŞ Y., ÇAPAN Y.
2nd International Gazi Symposium Series, 11 - 13 October 2017
- VI. **Transferrine hedeflendirilmiş paklitaksel yüklü PLGA nanopartiküllerinin meme kanserindeki etkinliği**
TONBUL H., ŞAHİN A., ÖZTÜRK N., VURAL İ., KAYNAK M. S., ÇAPAN Y.
1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu (ANES), Turkey, 1 June - 02 January 2017
- VII. **Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles Lessons and Challenges**
ŞAHİN A., Yerlikaya F., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
GPEN 2016, 9 - 12 November 2016
- VIII. **Drug Delivery with Targeted Nanoparticles: in Vitro and in Vivo Evaluation Methods.**
ÇAPAN Y.
17th International Pharmaceutical Technology Symposium, 18 - 21 October 2016
- IX. **Intracellular delivery and intraperitoneal retention of different sized PLGA nanoparticles prepared by nanoprecipitation method**
ŞAHİN A., ESENDAĞLI G., Fırat Y., Serhat K., Yöyen Ermis D., Horzum U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 - 21 September 2016
- X. **Development and in vitro evaluation of transferrin targeted PLGA nanoparticle**
TONBUL H., ŞAHİN A., KAYNAK M. S., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 19 - 21 September 2016
- XI. **Co Encapsulation Studies of Doxorubicin and Celecoxib in PLGA Nanoparticles**
Kozlu S., ŞAHİN A., Sevda Ş., Yerlikaya F., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 September 2916 - 21 September 2016
- XII. **Brain drug delivery**
ÇAPAN Y.
International Conference on Advances in the Area of Bioequivalance, Pharmaceutical Technology Symposium, 14 November 2015
- XIII. **Particle Size Optimization of Ibuprofen Loaded PLGA Nanoparticles Using Box Behnken Design**
ŞAHİN A., Çaban S., AKTAŞ Y., ÇAPAN Y.
AAPS 2015 Annual Meeting, 25 - 29 October 2015
- XIV. **Effects of Combined Surfactants in the Formulation of Docetaxel Loaded PLGA Nanoparticles**
Abdykerim Kyzy G., Çaban S., ŞAHİN A., ÇAPAN Y.
AAPS Annual Meeting 2015, 25 - 29 October 2015
- XV. **Determination of Critical Parameters of Paclitaxel and Flurbiprofen Co Loaded PLGA Nanoparticles Prepared By Nanoprecipitation**
ŞAHİN A., Çaban S., Abdykerim Kyzy G., Yerlikaya F., AKTAŞ Y., ÇAPAN Y.

AAPS Annual Meeting 2015, 25 - 29 October 2015

- XVI. Nanoscale drug delivery systems and the blood-brain barrier**
ÇAPAN Y.
17th International Pharmaceutical Technology Symposium, 8 - 10 September 2014
- XVII. Nanoparticulate Drug Delivery Systems Pharmaceutical Applications**
ÇAPAN Y.
IAEA Regional Training Course on "Radiation Synthesis and Characterization of Nanostructures, 8 - 12 November 2010
- XVIII. Brain Drug Targeting**
ÇAPAN Y.
15th International Pharmaceutical Technology Symposium, 13 - 15 October 2010
- XIX. The importance of particle size analysis: Its role in pharmaceutical development**
ÇAPAN Y.
United States Pharmacopeia and Ekin Kimya 4th Science Standards Symposium, 15 October 2010
- XX. Brain Drug Targeting**
ÇAPAN Y.
6th International Biomedical Science and Technology Symposium, 28 September - 02 October 2010
- XXI. Brain Drug Targeting IMPPS-3**
ÇAPAN Y.
Third International Meeting On Pharmacy Pharmaceutical Sciences, 9 - 12 June 2010
- XXII. Evaluation of the products with the same formula on the point of pharmaceutical technology**
ÇAPAN Y.
Turkish Society of Hematology Updating on Hematological Oncology Meeting, 6 - 09 May 2009
- XXIII. Bioavailability Bioequivalence**
ÇAPAN Y.
BioInternational 2008, 22 - 24 October 2008
- XXIV. Blood Brain Barrier Delivery with Molecular Trojan Horses**
ÇAPAN Y.
14th International Pharmaceutical Technology Symposium, 6 - 10 September 2008
- XXV. Perspectives in drug release from micro- and nanoparticulate drug delivery systems**
ÇAPAN Y.
14th International Pharmaceutical Technology Symposium, 6 - 10 September 2008
- XXVI. Bioavailability and Bioequivalence**
ÇAPAN Y.
34. National Haematology Congress, 10 - 11 August 2008
- XXVII. Technological Factors Influencing BA / BE**
ÇAPAN Y.
FATUM Symposium on Bioavailability / Bioequivalence and Regulatory Issues, 17 - 18 March 2008
- XXVIII. Recent Advances in Brain Drug Delivery**
ÇAPAN Y.
16th International Symposium on Microencapsulation, 09 September 2007
- XXIX. BE practice and issues in Turkey**
ÇAPAN Y.
Biointernational 2005, 24 - 25 October 2005
- XXX. An overview of dissolution and bioequivalence**
ÇAPAN Y.
Hands-On-Dissolution Workshop, 10 - 11 October 2005
- XXXI. Nanoparticle technology its Pharmaceutical Applications**
ÇAPAN Y.
FIP Meeting, 01 January 2005
- XXXII. Preparation and Characterization of Basic Fibroblast Growth Factor (bFGF)-Loaded**

Microparticulate Drug Delivery Systems,

ÇETİN M., ÇAPAN Y., VURAL İ., GÜRSOY R. N., DALKARA T., Cuine A., HINCAL A.

2004 AAPS Annual Meeting and Exposition, Maryland, United States Of America, 31 October 2004

XXXIII. Mitoxantrone Loaded Albumin Microspheres and Cytotoxicity Against Acute Promyelocytic Leukemia Cells

ÇAPAN Y.

7th US-Japan Symposium on Drug Delivery systems, 14 - 19 December 2003

XXXIV. Dissolution rate, Influence of Technological Parameters on Dissolution Rate, and Evaluation of Dissolution Rate Data

ÇAPAN Y.

7th International Symposium on Pharmaceutical Sciences, 23 - 27 June 2003

XXXV. Overview of Bioavailability/Bioequivalence Studies in Turkey

ÇAPAN Y.

ISHDRLP 2 (International Symposium on Harmonization and Drug Registration and Licensing Procedures), 9 - 11 September 2001

XXXVI. Preparation and Characterization of Poly (D,L-lactide-co-glycolide) Microspheres For Controlled Release of Poly (L-Lysine) Complexed Plasmid DNA

ÇAPAN Y.

8th Biomedical Science and Technology Symposium, 5 - 08 September 2000

Supported Projects

ÇAPAN Y., Ultav G., AKBAŞ S., Project Supported by Higher Education Institutions, Meme kanseri tedavisinde kullanılmak üzere farklı boyutlara sahip pH Duyarlı mezogözenekli silika nanopartiküllerinin geliştirilmesi optimizasyonu ve etkinliklerinin in vitro testlerle değerlendirilmesi, 2016 - 2017

ÇAPAN Y., Project Supported by Higher Education Institutions, 2016 AAPS Kongresine Katılım Desteği, 2016 - 2016

ÇAPAN Y., Project Supported by Higher Education Institutions, Farmasötik Teknoloji Alanındaki Gelişmelerin Takip Edilmesi ve Uluslararası Nitelikte Bilgi Paylaşımının Sağlanması, 2015 - 2016

ÇAPAN Y., ŞAHİN A., Project Supported by Higher Education Institutions, Beyin Kanseri Üzerinde Etkili Nanopartikül Formülasyonlarının Geliştirilmesi ve İn Vitro Etkinliklerinin Değerlendirilmesi, 2014 - 2015

Metrics

Publication: 92

Citation (WoS): 944

Citation (Scopus): 1123

H-Index (WoS): 15

H-Index (Scopus): 16